In the Claims:

1. (currently amended) A transdermal pharmaceutical preparation for the treatment of Parkinson's disease containing a combination of at least two active substances, wherein said pharmaceutical preparation contains a combination selected from the group of combinations of active substances consisting of:

~~a combination of a dopamine agonist and an anticholinergically active substance, wherein said dopamine agonist is selected from the group consisting of lisuride, bromocriptine, pramipexole, ropinirole, rotigotine, terguride, cabergoline, piribedile, pergolide and 4-propyl-9-hydroxynaphthoxazine (PHNO);~~

a combination of L-dopa and an anticholinergically active substance, said anticholinergically active substance being selected from the group consisting of bornaprine[[,]] and metixene ~~and orphenadrine~~;

a combination of a dopamine agonist and an NMDA receptor antagonist; and

a combination of L-dopa and an NMDA receptor antagonist.

2. (withdrawn) The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation contains a combination of three active substances selected from the group consisting of:

a combination of a dopamine agonist or L-dopa, an anticholinergically active substance, and an NMDA receptor antagonist and

a combination of a dopamine agonist or L-dopa, an anticholinergically active substance, and a monoamine oxidase B inhibitor.

3. (withdrawn) The pharmaceutical preparation according to claim 1, wherein the group

of dopamine agonists is selected from the group consisting of lisuride, bromocriptine, pramipexol, ropinirole, rotigotine, terguride, carbergoline, apomorphine, piribedile, pergolide and 4-propyl-9-hydroxynaphthoxazine (PHNO).

4. (withdrawn) The pharmaceutical preparation according to claim 2, wherein the group of monoamine oxidase inhibitors comprises monoamine oxidase B-selective inhibitors.

5. (canceled)

6. (withdrawn) The pharmaceutical preparation according to claim 1, wherein the group of the NMDA receptor antagonists comprises memantine and amantadine.

7. (withdrawn) The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation further contains an active substance selected from the group of the sympathomimetics.

8. (withdrawn) The pharmaceutical preparation according to claim 7, wherein the group of sympathomimetics comprises an active substance selected from the group consisting of the phenylethylamine derivatives.

9. (withdrawn) The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation additionally contains at least one further active substance selected from the group consisting of catechol-O-methyl transferase inhibitors and decarboxylase inhibitors.

10. (withdrawn) The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation additionally contains at least one active substance selected from the group consisting of the beta blockers.

11. (canceled)

12. (previously presented) The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation is a transdermal therapeutic system in the form of an active substance patch adhering to the skin.

13. (previously presented) The pharmaceutical preparation according to claim 12, wherein said transdermal therapeutic system comprises different layers or compartments for containing said combination of at least two active substances, and wherein at least two active substances of the active substance combination are contained in different layers or compartments of the transdermal therapeutic system.

14. (withdrawn) The pharmaceutical preparation according to claim 4, wherein said monoamine oxidase B-selective inhibitors are selegiline.

15. (withdrawn) The pharmaceutical preparation according to claim 8, wherein said phenylethylamine derivatives are, 3,4-methylenedioxymethamphetamine.

16. (withdrawn) The pharmaceutical preparation according to claim 9, wherein said at least one further active substance is selected from the group consisting of entacapone, benserazide and carbidopa.

17. (withdrawn) The pharmaceutical preparation according to claim 10, wherein said beta blockers are selected from the group consisting of propranolol, timolol, pindolol and atenolol.

18. (withdrawn) A transdermal pharmaceutical preparation for the treatment of Parkinson's disease, wherein said pharmaceutical preparation contains selegiline and rotigotine.

19. (previously presented) The pharmaceutical preparation according to claim 1, wherein

the preparation comprises two or more transdermal therapeutic systems (TTSs), and wherein each of said two or more transdermal therapeutic systems contains at least one active substance of said combination of at least two active substances.

20. (previously presented) The pharmaceutical preparation according to claim 5, further containing an active substance selected from the group consisting of biperidene, trihexyphenidyl, procyclidine, scopolamine, atropine, benzatropine and nicotine.

21. (previously presented) The pharmaceutical preparation according to claim 1, wherein said dopamine agonist is selected from the group consisting of lisuride, terguride, pergolide and cabergoline.

22. (previously presented) The pharmaceutical preparation according to claim 1, wherein said dopamine agonist is selected from the group consisting of pramipexole and piribedile.

23. (previously presented) The pharmaceutical preparation according to claim 1, wherein said dopamine agonist is selected from the group consisting of ropinirole and rotigotine.

24. (canceled)

25. (previously presented) A transdermal pharmaceutical preparation for the treatment of Parkinson's disease containing a combination of at least two active substances, wherein said pharmaceutical preparation contains a combination selected from the group consisting of:

a combination of a dopamine agonist and an anticholinergically active substance;

a combination of L-dopa and an anticholinergically active substance;

a combination of a dopamine agonist and an NMDA receptor antagonist; and

a combination of L-dopa and an NMDA receptor antagonist;

wherein the preparation comprises two or more transdermal therapeutic systems (TTSs), wherein each of said two or more transdermal therapeutic systems contains at least one active substance of said combination of at least two active substances.

26. (previously presented) The pharmaceutical preparation according to claim 1, wherein a daily dose of said active substance combination released from said preparation is in the range of from 0.1 mg to 50 mg.

27. (canceled)

28. (previously presented) The pharmaceutical preparation according to claim 25, wherein a daily dose of said active substance combination released from said preparation is in the range of from 0.1 mg to 50 mg.